AstraZeneca, Avillion ‘first-in-class’ combination inhaler shines in Phase 3 trial
An albuterol/budesonide fixed-dose combination rescue medication has been shown to reduce severe exacerbations in patients with asthma for the first time, according to positive Phase 3 trial results announced by AstraZeneca and Avillion. Asthma affects as many as 339 million adults and children around the world. Regardless of severity, the condition means that these patients […]